Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Monofer, injektions- og infusionsvæske, opløsning
Lacuna Pharma Pty Ltd
Chronic Heart Failure
1 trial -
Mycofit, 250 mg, kapsułki twarde, volrustomig, Saline, Remsima 100 mg powder for concentrate for solution for infusion
AstraZeneca AB
Locally advanced cervical cancer
1 trial -
Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, Lynparza 100 mg film-coated tablets, Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Imfinzi 50 mg/ml, Lynparza 100 mg, Lynparza 150 mg, Myfenax 250 mg hard capsules, Flixabi 100 mg p
AstraZeneca AB
Endometrial Cancer
1 trial -
NEORAL® Soft Gelatin Capsules 100mg, Methotrexate 2.5 mg Tablets, Zilbrysq 16.6 mg solution for injection in pre-filled syringe, Prednisolone 5mg Tablets, Azathioprine Tablets 50mg Oprisine, Privigen 100 mg/ml solution for infusion, Soliris 300 mg concentrate for solution for infusion, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 50mg, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 10mg, Methotrexate 2.5 mg Tablets, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 25mg, K
Kyverna Therapeutics
Generalized myasthenia gravis
1 trial -
NIO752, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung
Novartis Pharmaceuticals
Participants with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
1 trial -
NORADRENALINA TARTRATO MONICO 2 mg/ml Concentrato per soluzione per infusione
Lacuna Pharma Pty Ltd
criticall illness
1 trial -
Nacubactam, Imipenem/Cilastatin Kabi 500 mg/500 mg Pulver zur Herstellung einer Infusionslösung, Cefepim PANPHARMA 2 g Pulver zur Herstellung einer Injektions- bzw. Infusionslösung, AZACTAM 1 g, poudre et solution pour usage parentéral
Lacuna Pharma Pty Ltd
Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP)
1 trial -
Napabucasin, Bendatax 6 mg/ ml, Bendacitabin 38 mg/ml Pulver zur Herstellung einer Infusionslösung
The George Institute
Histologically or cytologically confirmed advanced pancreatic adenocarcinoma that is metastatic.
1 trial -
Neofordex 40 mg tablets, Imnovid 4 mg hard capsules, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, Imnovid 2 mg hard capsules, Privigen 100 mg/ml solution for infusion, ELRANATAMAB, Imnovid 3 mg hard capsules
Pfizer Australia Pty Ltd
MULTIPLE MYELOMA
1 trial -
Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion, avalglucosidase alfa, Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion
Sanofi-aventis Healthcare Pty Ltd
Glycogen storage disease type II
1 trial -
Niraparib Placebo Capsules, Niraparib Placebo Tablets, G5W (5% glucose in water), JEMPERLI 500 mg concentrate for solution for infusion
TESARO Bio Netherlands B.V.
Recurrent or primary advanced (Stage III or IV) endometrial cancer
1 trial -
Niraparib Placebo Tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion
GlaxoSmithKline
Lung Cancer, Non-Small Cell
1 trial -
Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion.
Bristol-Myers Squibb Australia Pty Ltd
Participants with completely resected Stage III or Stage IV melanoma
1 trial -
Nivolumab Subcutaneous, OPDIVO 10 mg/mL concentrate for solution for infusion.
Bristol-Myers Squibb Australia Pty Ltd
Metastatic Clear Cell Renal Cell Carcinoma
1 trial -
NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection, Voncento 250 IU FVIII / 600 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion, ADVATE 1 500 IU/2 ml powder and solvent for solution for injection, Voncento 500 IU FVIII / 1200 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion, ELOCTA 500 IU Powder and solvent for solution for injection, ELOCTA 750 IU Powder and solvent for solution for injection, ELOCTA 2000 IU Powder and solvent for
Hoffmann-La Roche
Type 3 Von Willebrand Disease
1 trial -
OAV101B, Zolgensma 2 × 10^13 vector genomes/mL solution for infusion
Novartis Pharmaceuticals
Spinal Muscular Atrophy
1 trial -
OCTAGAM 10 %, Lösung zur intravenösen Infusion, Cytarabine 20 mg/ml Solution for Injection/Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Prednisolone 5mg Tablets, Methotrexate 10 mg Tablets, Vinblastine Sulfate 1 mg/ml Solution for Injection or Infusion, Melphalan 50 mg Powder and Solvent for Solution for Injection/Infusion, INDOMETACIN CAPSULES BP 25mg, LEMTRADA 12 mg concentrate for solution for infusion, Mercaptopurine Silver Pharma 50 mg tablets, LITAK 2 mg
The George Institute
Langerhans Cell Histiocytosis
1 trial -
OFC Infusion
Novartis Pharmaceuticals
Leukaemia, Lymphocytic, Chronic
1 trial -
OPDIVO 10 mg/mL concentrate for solution for infusion.
Disc Medicine
oesophageal cancer
1 trial -
OPDIVO 10 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, BI 1810631, Tecentriq 1 200 mg concentrate for solution for infusion
Boehringer Ingelheim
Non-small cell lung cancer
1 trial -
OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, Sodium chloride 0.9%, solution for infusion, 5% Dextrose, solution for infusion
Bristol-Myers Squibb Australia Pty Ltd
Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors
1 trial -
OPDIVO 10 mg/mL concentrate for solution for infusion., LENVATINIB, YERVOY 5 mg/ml concentrate for solution for infusion, Sorafenib 200mg Film-Coated Tablets
Bristol-Myers Squibb Australia Pty Ltd
Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma
1 trial -
OPDIVO 10 mg/mL concentrate for solution for infusion., Nivolumab/Relatlimab
Bristol-Myers Squibb Australia Pty Ltd
Previously Untreated Metastatic or Unresectable Melanoma
1 trial -
OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, LENVIMA 10 mg hard capsules, AXITINIB SANDOZ 5 mg, comprimé pelliculé, CABOMETYX 40 mg film-coated tablets
The George Institute
Metastatic renal cell carcinoma (mRCC)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources